- Agriculture
- Antibiotic/anti-viral
- Biologics ×
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology x
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
A novel T-cell-based immunotherapy for brain cancer
Unmet Need Cancer immunotherapy represents a new paradigm in cancer treatment with the goal of harnessing the immune system to selectively attack a patient’s tumor. T-cell-based immunotherapies encompass chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes,…
Adoptive T-cell immunotherapy to treat cancer caused by Epstein-Barr virus
Unmet Need Epstein-Barr virus (EBV) is an infectious disease that has been shown to cause a number of cancers originating from EBV-afflicted cells. Across the globe, EBV is associated with approximately 200,000 cases of malignancies…
Anti-LYPD3 CAR T-cell therapy for the treatment of squamous cell carcinoma
Unmet Need Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy, has proven highly effective against blood cancers such as leukemias and lymphomas. This therapy uses T-cells that are genetically engineering ex vivo to…
Anti-cancer therapeutic for the induction of apoptosis in solid tumors via TRAIL receptors
Unmet Need Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL, CD253) acts as an activator of apoptosis in many tumor cells, while remaining innocuous to normal cells. Both membrane-bound and soluble forms of TRAIL can trigger apoptosis…
Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy
Unmet Need In the United States alone, over 1.8 million new patients were diagnosed with cancer in 2021, and over 600,000 patients died from the disease. Cytostatic nucleotides, such as gemcitabine and 5-fluorouracil, have been…
A class of biodegradable stealth polymers to improve drug delivery
Unmet Need Delivery of drugs or therapeutics such as small molecules, peptides, and proteins, in their native form, is limited by their poor stability, low solubility, and short in vivo circulation. These challenges in drug…
A method for treating TRAIL-resistant cancers
Unmet Need Over the past twenty years, TNF-related apoptosis-inducing ligand (TRAIL) has been shown to kill a variety of human cancer cells in vitro and in vivo while remaining innocuous to healthy cells. Unfortunately, the…